Want to see IN:MANKIND full AI Analyst Report?
Mankind Pharma Ltd. (MANKIND) Stock Price & Analysis
MANKIND Stock Chart & Stats
- Day’s Range
- INR 2,497.85 - INR 2,573.10
- 52-Week Range
- INR 1,909.90 - INR 2,640.30
- Previous Close
- INR 2,533.15
- Volume
- 185.79K
- Average Volume (3M)
- 59.19K
- Market Cap
- INR 1.05T
- Enterprise Value
- INR 1.07T
- Total Cash (Recent Filing)
- INR 26.60B
- Total Debt (Recent Filing)
- INR 54.22B
- Price to Earnings (P/E)
- 46.3
- Beta
- 0.51
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 12.55
- Last Dividend Ex-Date
- Aug 08, 2025
- Dividend Yield
- 0.04%
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Growth
Strong top-line growth combined with faster EBITDA expansion indicates operating leverage and improving profitability. If sustained, this performance can strengthen internal funding capacity, support brand investment, and improve earnings resilience across the next several quarters.
International Expansion
Rapid international growth broadens Mankind Pharma’s revenue base beyond domestic prescriptions and creates additional channels for branded specialty products. Continued overseas expansion can diversify demand, improve scale, and provide a durable contributor to medium-term growth.
Debt Reduction
Falling net debt and low net leverage improve financial flexibility and reduce the burden of acquisition-related financing. Completing the repayment plan should support stronger balance-sheet resilience, lower financing pressure, and greater capacity for strategic investment.
Bears Say
Consumer Healthcare Slowdown
Softer consumer healthcare demand limits the contribution from a significant business stream and shows that category growth is not currently keeping pace with the broader portfolio. A delayed recovery could restrain consolidated growth and reduce operating leverage.
Higher Effective Tax Rate
The step-up in the effective tax rate reduces the portion of operating profit that converts into earnings and cash available for reinvestment. Because the change followed expiry of the tax exemption period, it represents a recurring structural headwind rather than a temporary quarterly effect.
Weaker Cash Conversion
Higher working-capital intensity is absorbing more cash as sales grow, weakening the conversion of reported operating profit into liquidity. If this persists, it could limit internally funded expansion, increase financing needs, and make earnings quality more dependent on working-capital management.
Mankind Pharma Ltd. News
MANKIND FAQ
What was Mankind Pharma Ltd.’s price range in the past 12 months?
What is Mankind Pharma Ltd.’s market cap?
When is Mankind Pharma Ltd.’s upcoming earnings report date?
How were Mankind Pharma Ltd.’s earnings last quarter?
Is Mankind Pharma Ltd. overvalued?
Does Mankind Pharma Ltd. pay dividends?
What is Mankind Pharma Ltd.’s EPS estimate?
How many shares outstanding does Mankind Pharma Ltd. have?
What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mankind Pharma Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Mankind Pharma Ltd.
Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its pharmaceutical division focuses on both acute and chronic therapeutic areas, encompassing a wide spectrum of medical conditions such as infectious diseases, cardiovascular ailments, gastrointestinal disorders, diabetes, dermatology, pain management, neuro/CNS issues, nutritional support (vitamins/minerals), and respiratory problems. Complementing its pharmaceutical portfolio, the consumer healthcare segment offers diverse products, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. Key brands under its umbrella include Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Furthermore, the company's business activities are diversified, extending to the trading and export of pharmaceutical and healthcare products, as well as the manufacturing of various goods such as packaging materials, ayurvedic products, bulk drugs, and general consumer items. Mankind Pharma also holds interests in real estate, leasing, hospitality, and IT services. Established in 1986, Mankind Pharma Limited maintains its headquarters in New Delhi, India.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sheetal Arora
- Employees
- 20,451
- Website
- www.mankindpharma.com
- Address
- 262, Okhla Industrial Estate, New Delhi, DE, 110 020, IN
Mankind Pharma Ltd. (MANKIND) Earnings & Revenues
MANKIND Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, characterized by double-digit revenue growth, improved EBITDA and PAT margins, domestic outperformance versus IPM, accelerating volume growth, robust BSV and international momentum, brand portfolio expansion, and debt reduction. The main challenges were softer consumer healthcare performance, a higher effective tax rate, increased working capital, and the ongoing recovery of anti-infectives. Management maintained a confident outlook, including expectations for continued IPM outperformance and double-digit international growth.
View all IN:MANKIND earnings summariesMANKIND Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:ALKEMAlkem Laboratories Ltd. | ||
| IN:LUPINLupin Limited | ||
| IN:SUNPHARMASun Pharmaceutical Industries Limited | ||
| IN:TORNTPHARMTorrent Pharmaceuticals Ltd | ||
| IN:ZYDUSLIFEZydus Lifesciences Limited |
